Continued here:
New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia

Read more from the original source:
Eupraxia Pharmaceuticals Announces Closing of Overnight Marketed Offering for Gross Proceeds of C$33.9 Million

Here is the original post:
Avenue Therapeutics Receives Positive Listing Determination from Nasdaq

See the rest here:
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity

Go here to read the rest:
Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024

Read more here:
Scilex Holding Announces Issuance of Halal Certification for its ZTlido® product by Circle H International, Inc.

See the original post:
Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer

Follow this link:
Scilex Holding Company’s Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Entered into a Definitive Mutual Release and Settlement Agreement...

Read more here:
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps

Link:
Sanofi: Information concerning the total number of voting rights and shares - February 2024

Read more from the original source:
NurExone's Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence

Here is the original post:
Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

Originally posted here:
Financière de Tubize - Annual report 2023

Read the original:
Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares

See the original post here:
Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed

Excerpt from:
Idorsia and Viatris successfully close the transaction for the global research and development collaboration

See the original post:
Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand

Link:
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update

Read more:
Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results

See more here:
Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights